Publication Name	World Journal of Clinical Oncology
Manuscript ID	66382
Country	Spain

Received	2021-03-26 15:59
Peer-Review Started	2021-03-26 16:02
First Decision by Editorial Office Director	2021-06-16 04:53
Return for Revision	2021-06-16 04:53
Revised	2021-06-22 07:26
Publication Fee Transferred
Second Decision by Editor	2021-10-21 06:25
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2021-10-25 02:07
Articles in Press	2021-10-25 02:07
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-11-17 06:04
Publish the Manuscript Online	2021-11-19 09:32

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Retrospective Study
Article Title	Pathological response to neoadjuvant therapy with chemotherapy vs chemoradiotherapy in stage III NSCLC. Contribution of IASLC recommendations
Manuscript Source	Invited Manuscript
All Author List	Diego Muñoz-Guglielmetti, David Sanchez-Lorente, Roxana Reyes, Daniel Martinez, Carmen Lucena, Marc Boada, Pilar Paredes, Marta Parera-Roig, Ivan Vollmer, Joel Mases, Roberto Martin-Deleon, Sergi Castillo, Mariana Benegas, Silvia Muñoz, Maria Mayoral, Carla Cases, Meritxell Mollà and Francesc Casas
ORCID	Author(s) ORCID Number Diego Muñoz-Guglielmetti http://orcid.org/0000-0002-1857-8930 David Sanchez-Lorente http://orcid.org/0000-0003-3308-4696 Roxana Reyes http://orcid.org/0000-0001-9035-4491 Daniel Martinez http://orcid.org/0000-0001-7492-5311 Carmen Lucena http://orcid.org/0000-0001-8265-3918 Marc Boada http://orcid.org/0000-0002-3801-4497 Pilar Paredes http://orcid.org/0000-0002-8097-9217 Marta Parera-Roig http://orcid.org/0000-0001-8571-4878 Ivan Vollmer http://orcid.org/0000-0002-8051-3994 Joel Mases http://orcid.org/0000-0002-7991-7932 Roberto Martin-Deleon http://orcid.org/0000-0002-2786-1084 Sergi Castillo http://orcid.org/0000-0003-0402-9612 Mariana Benegas http://orcid.org/0000-0003-0585-5609 Silvia Muñoz http://orcid.org/0000-0002-3265-5306 Maria Mayoral http://orcid.org/0000-0003-0108-3226 Carla Cases http://orcid.org/0000-0003-2110-9016 Meritxell Mollà http://orcid.org/0000-0001-6215-2251 Francesc Casas http://orcid.org/0000-0001-6464-0603
Funding Agency and Grant Number
Corresponding Author	Diego Muñoz-Guglielmetti, MD, Doctor, Doctor, Radiation Oncology, Hospital Clínic de Barcelona, Carrer de Villarroel 170, Barcelona 08036, Cataluña, Spain. dimunoz@clinic.cat
Key Words	Non-small cell lung cancer; Chemotherapy; Chemoradiotherapy; Neoadjuvant treatment; Resectable stage III; Pathological response
Core Tip	Preoperative chemotherapy (Ch) has become a standard treatment option, especially in resectable stage III (primarily N2) non-small cell lung cancer (NSCLC). Phase II and phase III studies have raised the question as to whether preoperative Ch plus radiotherapy provides any additional benefits to preoperative Ch. The objective of our retrospective study was to contribute (with an experienced team of medical oncologists, radiation oncologists, thoracic surgeons, and pathologists) to the International Association for the Study of Lung Cancer recommendations in relation to differences in the pathological evaluation of tumors and mediastinal and hilar nodes in resectable stage III NSCLC, comparing neoadjuvant Ch vs chemoradiotherapy.
Publish Date	2021-11-19 09:32
Citation	Muñoz-Guglielmetti D, Sanchez-Lorente D, Reyes R, Martinez D, Lucena C, Boada M, Paredes P, Parera-Roig M, Vollmer I, Mases J, Martin-Deleon R, Castillo S, Benegas M, Muñoz S, Mayoral M, Cases C, Mollà M, Casas F. Pathological response to neoadjuvant therapy with chemotherapy vs chemotherap-radiotherapy in stage III NSCLC. Contribution of IASLC recommendations. World J Clin Oncol 2021; 12(11): 1047-1063
URL	https://www.wjgnet.com/2218-4333/full/v12/i11/1047.htm
DOI	https://dx.doi.org/10.5306/wjco.v12.i11.1047

Full Article (PDF)	WJCO-12-1047.pdf
Full Article (Word)	WJCO-12-1047.docx